Visit Our HIV Medicines

Find Medical Information organized by product. Explore now

CONGRESS PRESENTATIONS

ID Week 2023

October 11-15, 2023
Boston, Massachusetts

2023 Post Fall Conference

Scientific Engagement Webinar - with panel discussion

ON DEMAND

Cabotegravir Treatment

Garris C, et al.

Real-world adherence and persistence with long-acting cabotegravir plus rilpivirine (CAB+RPV LA) compared to oral antiretroviral therapy (ART) among people with HIV (PWH) in the US: the ABOVE study
View
Download
×

Garris C, et al.

Real-world adherence and persistence with long-acting cabotegravir plus rilpivirine (CAB+RPV LA) compared to oral antiretroviral therapy (ART) among people with HIV (PWH) in the US: the ABOVE study
Title
Disclosures
Importance of adherence in HIV and role of Cabotegravir + Rilpivirine long-acting (CAB+RPV LA)
Objectives
Study design
Analysis
Baseline characteristics
Baseline characteristics were balanced after weighting
Prior oral art regimen
CAB+RPV LA Treatment patterns
Adherence
Persistence
Adherence to CAB+RPV LA was high across all subgroups
Limitations
Conclusions
Thank you
Disclaimer
Collapse ❯ Expand ❮
Download

Sinclair G, et al.

Clinical outcomes at month 6 after initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND)
View
Download
×

Sinclair G, et al.

Clinical outcomes at month 6 after initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND)
Collapse ❯ Expand ❮
Download

Dandachi D, et al.

Perspectives of people with HIV (PWH) 6 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND)
View
Download
×

Dandachi D, et al.

Perspectives of people with HIV (PWH) 6 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND)
Collapse ❯ Expand ❮
Download

McKellar MS, et al.

SOLAR 12-month North American results: randomized switch trial of CAB+RPV LA vs. oral BIC/FTC/TAF
View
Download
×

McKellar MS, et al.

SOLAR 12-month North American results: randomized switch trial of CAB+RPV LA vs. oral BIC/FTC/TAF
Collapse ❯ Expand ❮
Download

Cabotegravir Prevention

Torres JA, et al.

Healthcare staff perceptions of feasibility and acceptability on implementing injectable HIV pre-exposure prophylaxis into standard of care: baseline results from the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)
View
Download
×

Torres JA, et al.

Healthcare staff perceptions of feasibility and acceptability on implementing injectable HIV pre-exposure prophylaxis into standard of care: baseline results from the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)
Collapse ❯ Expand ❮
Download

Richmond T, et al.

Engaging black women on cabotegravir LA for PrEP by optimizing novel implementation strategies (EBONI) study: provider perceptions of appropriateness cabotegravir LA for PrEP for cis- and- trans black women
View
Download
×

Richmond T, et al.

Engaging black women on cabotegravir LA for PrEP by optimizing novel implementation strategies (EBONI) study: provider perceptions of appropriateness cabotegravir LA for PrEP for cis- and- trans black women
Collapse ❯ Expand ❮
Download

Valenti W, et al.

Integrating long-acting injectable cabotegravir for PrEP into standard of care for cisgender women, transgender women, transgender men, and men who have sex with men: results from the PILLAR & EBONI studies
View
Download
×

Valenti W, et al.

Integrating long-acting injectable cabotegravir for PrEP into standard of care for cisgender women, transgender women, transgender men, and men who have sex with men: results from the PILLAR & EBONI studies
Collapse ❯ Expand ❮
Download

Metzner AA, et al.

HIV acquisition following oral pre-exposure prophylaxis (PrEP) initiation
View
Download
×

Metzner AA, et al.

HIV acquisition following oral pre-exposure prophylaxis (PrEP) initiation
Collapse ❯ Expand ❮
Download

Davis W, et al.

Acceptability of an HIV pre-exposure prophylaxis (PrEP) shared decision-making tool for diverse populations and healthcare providers
View
Download
×

Davis W, et al.

Acceptability of an HIV pre-exposure prophylaxis (PrEP) shared decision-making tool for diverse populations and healthcare providers
Collapse ❯ Expand ❮
Download

Kerrigan D, et al.

Exploring cisgender women's HIV pre-exposure prophylaxis (PrEP) needs and preferences across settings: the role of social-structural factors
View
Download
×

Kerrigan D, et al.

Exploring cisgender women's HIV pre-exposure prophylaxis (PrEP) needs and preferences across settings: the role of social-structural factors
Collapse ❯ Expand ❮
Download

Poteat T, et al.

Risk Factors, Risk Perception, and Long-acting PrEP Awareness and Interest among US Women: A National Survey
View
Download
×

Poteat T, et al.

Risk Factors, Risk Perception, and Long-acting PrEP Awareness and Interest among US Women: A National Survey
Full Poster
Title
Key Takeaways
Introduction
Methods
Figure 1. Study Design and Objectives
Results
Figure 2. Awareness and Interest in Using Long-Acting PrEP Among US Women
Long-Acting PrEP Awareness
Long-Acting PrEP Interest
Conclusions
Disclaimer
Collapse ❯ Expand ❮
Download

Dolutegravir-based Regimens

Brogan AP, et al.

Virological Suppression in People with HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar across Age Groups despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis)
View
Download
×

Brogan AP, et al.

Virological Suppression in People with HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar across Age Groups despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis)
Collapse ❯ Expand ❮
Download

Fostemsavir Treatment

Dyson A, et al.

Durable efficacy and robust CD4+ T-Cell count improvement observed among age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
View
Download
×

Dyson A, et al.

Durable efficacy and robust CD4+ T-Cell count improvement observed among age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
Collapse ❯ Expand ❮
Download

This content was acquired following an unsolicited medical information enquiry by a healthcare professional.  Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license.  In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

Connect With Us

Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Yes

No

Connect With Our Medical Experts

Find My ViiV MSL

Easily find the ViiV Medical Science Liaison (MSL) in your area.

Talk to a Medical Expert

Connect now with a live ViiV Medical Expert.

Request a Scientific Discussion

Submit a request for additional information from a ViiV Medical Expert.

Contact Us

Chat Live

Get immediate assistance from a ViiV Healthcare Professional.

Call 1‑888‑226‑8434

Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)

Our Response to COVID-19

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch